These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37265260)

  • 1. Development of screening assays for use of broadly neutralizing antibodies in people with HIV.
    Lynch RM; Bar KJ
    Curr Opin HIV AIDS; 2023 Jul; 18(4):171-177. PubMed ID: 37265260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly neutralizing antibodies for HIV treatment and cure approaches.
    Frattari GS; Caskey M; Søgaard OS
    Curr Opin HIV AIDS; 2023 Jul; 18(4):157-163. PubMed ID: 37144579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.
    Williams WB; Wiehe K; Saunders KO; Haynes BF
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
    Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
    J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.
    Moldt B; Parvangada A; Martin R; Pace C; Balakrishnan M; Thomsen ND; E Collins S; Kuster H; Braun DL; Günthard HF; Geleziunas R; Callebaut C
    J Acquir Immune Defic Syndr; 2021 Sep; 88(1):61-69. PubMed ID: 34397744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
    Cohen YZ; Caskey M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):366-373. PubMed ID: 29697469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.
    Tu JJ; Kumar A; Giorgi EE; Eudailey J; LaBranche CC; Martinez DR; Fouda GG; Moreau Y; Thomas A; Montefiori D; Gao F; Sagar M; Permar SR
    J Virol; 2022 Jun; 96(11):e0023122. PubMed ID: 35536018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
    Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility.
    Registre L; Moreau Y; Ataca ST; Pulukuri S; Henrich TJ; Lin N; Sagar M
    J Virol; 2020 Jan; 94(2):. PubMed ID: 31694950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.
    Wagh K; Bhattacharya T; Williamson C; Robles A; Bayne M; Garrity J; Rist M; Rademeyer C; Yoon H; Lapedes A; Gao H; Greene K; Louder MK; Kong R; Karim SA; Burton DR; Barouch DH; Nussenzweig MC; Mascola JR; Morris L; Montefiori DC; Korber B; Seaman MS
    PLoS Pathog; 2016 Mar; 12(3):e1005520. PubMed ID: 27028935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
    Lee MJ; Collins S; Babalis D; Johnson N; Falaschetti E; Prevost AT; Ashraf A; Jacob M; Cole T; Hurley L; Pace M; Ogbe A; Khan M; Zacharopoulou P; Brown H; Sutherland E; Box H; Fox J; Deeks S; Horowitz J; Nussenzweig MC; Caskey M; Frater J; Fidler S
    Trials; 2022 Apr; 23(1):263. PubMed ID: 35382844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana.
    Moraka NO; Choga WT; Pema MN; Chawawa MK; Gobe I; Mokomane M; Bareng OT; Bhebhe L; Kelentse N; Mulenga G; Pretorius Holme M; Mohammed T; Koofhethile CK; Makhema JM; Shapiro R; Lockman S; Moyo S; Gaseitsiwe S
    Sci Rep; 2023 Oct; 13(1):18134. PubMed ID: 37875518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
    Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
    Thavarajah JJ; Hønge BL; Wejse CM
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic.
    Spencer DA; Shapiro MB; Haigwood NL; Hessell AJ
    Front Public Health; 2021; 9():690017. PubMed ID: 34123998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.